Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hand hygiene01:23

Hand hygiene

3.5K
Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
3.5K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

127
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
127
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

373
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
373
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

224
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
224
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

19
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RE: Comment on ''The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial''.

Journal of the American Academy of Dermatology·2026
Same author

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Journal of the American Academy of Dermatology·2026
Same author

Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.

Journal of the American Academy of Dermatology·2026
Same author

Response to "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX".

Journal of the American Academy of Dermatology·2026
Same author

Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.

Dermatology and therapy·2026
Same author

Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel.

Journal of drugs in dermatology : JDD·2026

Related Experiment Video

Updated: Aug 10, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Current management of generalized pustular psoriasis.

Nilesh Kodali1, Isabella Blanchard1, Sruthi Kunamneni1

  • 1Department of Education, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

Experimental Dermatology
|February 13, 2023
PubMed
Summary

Generalized pustular psoriasis (GPP) is a rare, inflammatory skin condition with severe systemic complications. This review updates global management strategies, focusing on the IL-36 pathway and emerging therapies.

Keywords:
GPPIL-36IL-36RNIL-36RaSpesolimabpsoriasissystemic inflammationtreatmentvon Zumbusch

More Related Videos

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

494
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

474

Related Experiment Videos

Last Updated: Aug 10, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

494
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

474

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Generalized pustular psoriasis (GPP) is a rare, severe inflammatory disease characterized by sterile pustules and systemic involvement.
  • GPP disproportionately affects females and individuals of Asian descent, with a critical role for the IL-1/IL-36 inflammatory pathway.
  • Associated genetic mutations include IL36RN, CARD14, AP1S3, MPO, and SERPINA3.

Purpose of the Study:

  • To provide an updated review of the global management of Generalized pustular psoriasis (GPP).
  • To discuss current understanding of GPP pathogenesis, diagnosis, clinical presentation, and epidemiology.
  • To highlight recent advancements in GPP treatment, including targeted therapies.

Main Methods:

  • Comprehensive literature review of GPP pathogenesis, diagnosis, and treatment.
  • Analysis of current global treatment guidelines and approved therapies.
  • Examination of genetic factors and inflammatory pathways implicated in GPP.

Main Results:

  • The IL-1/IL-36 pathway is central to GPP pathology, with specific genetic mutations identified.
  • Spesolimab, an IL-36 receptor antagonist, is the only approved GPP-specific treatment in the US; other anti-IL-36 therapies are in development.
  • Global treatment approaches vary, with biologics approved in some regions (e.g., Japan) but not others (e.g., UK, China).

Conclusions:

  • Current GPP treatment guidelines are evolving, with a growing focus on targeted IL-36 pathway inhibition.
  • Understanding the genetic and inflammatory basis of GPP is crucial for developing effective therapies.
  • Global disparities in treatment access and availability necessitate continued research and guideline harmonization.